On or around 03/29/2017 (Other)
Filing Date: December 30, 2015
According to the law firm press release, the Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Anavex had used a paid stock promoter to artificially inflate the Company’s share price; and (ii) as a result of the foregoing, Anavex’s public statements were materially false and misleading at all relevant times.
On April 5, 2016, the Court issued an Order appointing Lead Plaintiff and Lead Counsel. Lead Plaintiff filed an amended complaint on May 13.
On December 29, 2016, the Court issued an Order granting Defendants' Motion to Dismiss. Judgment in favor of Defendants was entered.
Company & Securities Information
Defendant: Anavex Life Sciences Corp
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AVXL
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Kevin Cortina, et al. v. Anavex Life Sciences Corp, et al.